ClinicalTrials.gg
CompletedNCT03397706Updated Mar 20, 2025Results posted

Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies

A Phase 1/2 interventional study of VRx-3996 and valganciclovir in Epstein-Barr Virus-Associated Lymphoma and Lymphoproliferative Disorders, sponsored by Viracta Therapeutics, Inc.. Completed at 28 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-20.

Sponsored by Viracta Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
64
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 147 studies in Lymphoproliferative Disorders with a site in United States — 28 open to participants now, 46 under way, 2 of them phase 3. Lymphoproliferative Disorders · United States.

Enrollment
45th of 127
64 · median 37
Started
2018
with 7 others
Phase 1/2
19 of 147
4 open now
Registered
106th of 147
by date

Among the 147 studies in Lymphoproliferative Disorders with a site in United States, this one is the 45th largest by enrollment of the 127 interventional ones that give a count, is one of 8 that started in 2018, is one of 19 in phase 1/2, and was the 106th registered.

Lymphoproliferative Disorders

216 studies on the registry are indexed under Lymphoproliferative Disorders; 49 are open to participants now.

Browse Lymphoproliferative Disorders studies →

Open to participants now

28 of the 147 studies in Lymphoproliferative Disorders with a site in United States are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 39 Lymphoproliferative Disorders studies recruiting now, 28 (72%) set no upper age limit and 6 (15%) stop at 75 or younger; 18 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies in Lymphoproliferative Disorders with a site in United States, or all of them as a file.
02

Study summary

A two part, Phase 1b/2 study to define a recommended Phase 2 dose of VRx-3996 in combination with valganciclovir (Phase 1b) designed to evaluate the efficacy of this combination in relapsed/refractory Epstein-Barr Virus Associated Lymphoma (EBV+ lymphomas).

Read the detailed description

The purpose of this study is to determine whether VRx-3996 in combination with valganciclovir is safe, determine the side effect profile, and to determine whether this therapy may help patients with EBV-related lymphomas. The study has two phases. Goals of the first phase include determining a safe and tolerable dose that can be administered in phase 2. Goals of the second phase include further evaluating the safety and tolerability of VRx-3996 in combination with valganciclovir, evaluating how the drugs are metabolized in the body, evaluating response rates and other exploratory objectives that will help the researchers evaluate how these drugs work in the body. Participants will receive daily oral doses of the two study drugs and will have multiple study visits where they will have blood collected, physical examinations, and other medical monitoring. Following completion of the Ph2, the study will enroll additional patients into a Tablet Pharmacokinetic (PK) cohort to investigate the PK parameters of the tablet formulation.

03

Conditions studied

  • Epstein-Barr Virus-Associated Lymphoma
  • Lymphoproliferative Disorders

Keywords

  • EBV-associated peripheral T-cell lymphoma
  • EBV-associated angioimmunoblastic T-cell lymphoma
  • EBV-associated diffuse large B-cell lymphoma
  • EBV-associated post-transplant lymphoproliferative disorder
  • EBV-associated extranodal NK/T-cell lymphoma
  • EBV-associated Hodgkin lymphoma
  • EBV-associated non-Hodgkin lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • , confirmed Epstein-Barr Virus positive (EBV+) lymphoid or lymphoproliferative disease
  • Absence of available therapy with reasonable likelihood of cure or significant clinical benefit
  • Adequate hematologic, hepatic and renal function as defined by laboratory assessment

Key Exclusion Criteria:

  • Known primary central nervous system (CNS) lymphoma
  • Known or unless appropriately treated and neurologically stable for at least 4 weeks
  • Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
  • Refractory (GvHD) not responding to treatment
  • Known active virus infection
  • Circulating virus on quantitative polymerase chain reaction (qPCR)
  • Known history of human herpes virus (HHV)-6 chromosomal integration
  • Known history of infection
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Phase 1b Dose Escalation

    VRx-3996 (cohort 1) and valganciclovir VRx-3996 (cohort 2) and valganciclovir VRx-3996 (cohort 3) and valganciclovir VRx-3996 (cohort 4) and valganciclovir VRx-3996 (cohort 5) and valganciclovir

    Combination Product: VRx-3996 and valganciclovir

  • Experimental
    Phase 2 Expansion - Capsule

    VRx-3996 and valganciclovir at the recommended Phase 2 dose (RP2D)

    Combination Product: VRx-3996 and valganciclovir

  • Experimental
    Phase 2 Expansion - Tablet

    VRx-3996 and valganciclovir at the recommended Phase 2 dose (RP2D)

    Combination Product: VRx-3996 and valganciclovir

Interventions

06

What researchers measure

Primary outcomes

  1. Number (Proportion) of Participants With Adverse Events (AEs)

    Number (percentage) of patients experiencing at least one treatment-emergent adverse event, defined as those untoward medical events with onset after the first dose of study drug or existing events that worsened after the first dose during the study

    Time frame: Up to approximately 2 years

  2. Number (Proportion) of Participants With Dose-Limiting Toxicities (DLTs) in Phase 1b

    Number (percentage) of patients experiencing a DLT during the first cycle (28 days) of study treatment in Phase 1b, defined as an adverse event (AE) or clinically significant abnormal laboratory value that was at least possibly related to study drugs and was not primarily related to disease, disease progression, concomitant medication(s), or intercurrent illness. In addition, to be considered a DLT, the AE had to meet at least one of the following criteria: * Grade 4 anemia unexplained by underlying disease * Grade 4 febrile neutropenia * Grade 4 neutropenia lasting \>5 days * Any other Grade 4 hematologic toxicity (thrombocytopenia, neutropenia, febrile neutropenia, anemia) of any duration * Grade 4 or higher tumor lysis syndrome * Grade 3 or higher thrombocytopenia (with or without bleeding) * Any requirement for platelet transfusion * Grade 3 or higher non-hematologic toxicity despite adequate supportive care * Results in a dose hold of \>7 consecutive days

    Time frame: Cycle 1 (28 days)

  3. Overall Response Rate

    Number (percentage) of patients with a best overall complete response (CR) or partial response (PR) according to the Lugano 2014 criteria (Cheson, Bruce D. et al. J Clin Oncology 2014;32(27):3059-68), where CR included complete metabolic response (no/minimal fluorodeoxyglucose \[FDG\] uptake) and radiologic response (target lesions regress to ≤1.5 cm in longest transverse diameter of a lesion) and no new lesions, and PR included partial metabolic response (reduced FDG uptake compared with baseline) or radiologic response (target lesions ≤ 50% decrease in the sum of the product of perpendicular diameters of up to 6 target measurable nodes and extranodal sites)

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Duration of Response

    Interval of time from date of first observed complete or partial response per Lugano 2014 criteria (Cheson BD et al. J Clin Oncology 2014;32(27):3059-68) to the date of documented disease progression or death due to any cause, where disease progression is defined by Lugano 2014 criteria (Cheson BD et al. J Clin Oncology 2014;32(27):3059-68) as progressive metabolic disease (increase in fluorodeoxyglucose \[FDG\] uptake from baseline or new FDG-avid foci consistent with lymphoma) or progressive radiologic response (increase in the product of perpendicular diameters of a single node by ≥ 50% or emergence of a new lesion)

    Time frame: Up to approximately 2 years

  2. Time to Response

    Interval of time from the start of study drug treatment to the first documentation of CR or PR per Lugano 2014 criteria (Cheson BD et al. J Clin Oncology 2014;32(27):3059-68)

    Time frame: Up to approximately 2 years

  3. Progression-Free Survival

    Interval of time from the date of first study drug administration to the documented date of disease progression or death, whichever occurred first, where disease progression is defined by Lugano 2014 criteria (Cheson BD et al. J Clin Oncology 2014;32(27):3059-68) as progressive metabolic disease (increase in fluorodeoxyglucose \[FDG\] uptake from baseline or new FDG-avid foci consistent with lymphoma) or progressive radiologic response (increase in the product of perpendicular diameters of a single node by ≥ 50% or emergence of a new lesion)

    Time frame: Up to approximately 2 years

  4. Disease Control Rate

    Number (percentage) of patients with CR, PR, or stable disease (SD) per Lugano 2014 criteria (Cheson BD et al. J Clin Oncology 2014;32(27):3059-68)

    Time frame: Up to approximately 2 years

  5. Overall Survival

    Interval of time from date of first study drug treatment to date of death, for any reason (patients without documentation of death at the time of analysis were censored at the date the patient was last known to be alive)

    Time frame: Up to approximately 2 years

  6. Cmax (ng/mL) of VRx-3996

    Pharmacokinetic (PK) assessment of VRx-3996 pre-dose and at hours 0.5, 1, 2, 4, and 6 post-dose on cycle 1 day 1 (C1D1) and cycle 2 day 2 (C2D1)

    Time frame: Phase 1b: Cycle 1 Day 1 and Phase 2: multiple doses through Cycle 2 Day 1

  7. Cmax (ng/mL) of Valganciclovir

    PK assessment of valganciclovir pre-dose and at hours 0.5, 1, 2, 4, and 6 post-dose on C1D1 and C2D1

    Time frame: Phase 1b: Cycle 1 Day 1 and Phase 2: multiple doses through Cycle 2 Day 1

  8. Area Under Curve (AUC) 0-t of VRx-3996

    PK assessment of VRx-3996 pre-dose and at hours 0.5, 1, 2, 4, and 6 post-dose on C1D1 and C2D1

    Time frame: Phase 1b: Cycle 1 Day 1 and Phase 2: multiple doses through Cycle 2 Day 1

  9. AUC 0-t of of Valganciclovir

    PK assessment of valganciclovir pre-dose and at hours 0.5, 1, 2, 4, and 6 post-dose on C1D1 and C2D1

    Time frame: Phase 1b: Cycle 1 Day 1 and Phase 2: multiple doses through Cycle 2 Day 1

  10. Half-life of VRx-3996

    PK assessment of VRx-3996 pre-dose and at hours 0.5, 1, 2, 4, and 6 post-dose on C1D1 and C2D1

    Time frame: Phase 1b: Cycle 1 Day 1 and Phase 2: multiple doses through Cycle 2 Day 1

  11. Half-life of Valganciclovir

    PK assessment of valganciclovir pre-dose and at hours 0.5, 1, 2, 4, and 6 post-dose on C1D1 and C2D1

    Time frame: Phase 1b: Cycle 1 Day 1 and Phase 2: multiple doses through Cycle 2 Day 1

07

Results

Posted Mar 20, 2025

Participant flow

Participant flow — Overall Study
MilestonePhase 1b Dose Escalation Cohort 1Phase 1b Dose Escalation Cohort 2aPhase 1b Dose Escalation Cohort 2bPhase 1b Dose Escalation Cohort 2cPhase 1b Dose Escalation Cohort 3Phase 2 Dose Expansion - CapsulePhase 2 Expansion - Tablet
Started75445309
Completed75445309
Not completed0000000

Outcome measures

PrimaryNumber (Proportion) of Participants With Adverse Events (AEs)

Number (percentage) of patients experiencing at least one treatment-emergent adverse event, defined as those untoward medical events with onset after the first dose of study drug or existing events that worsened after the first dose during the study

Time frame:
Up to approximately 2 years
Reported as:
Count of participants · Participants
Number (Proportion) of Participants With Adverse Events (AEs)
ParticipantsPhase 1b Dose Escalation Cohort 1Phase 1b Dose Escalation Cohort 2aPhase 1b Dose Escalation Cohort 2bPhase 1b Dose Escalation Cohort 2cPhase 1b Dose Escalation Cohort 3Phase 2 Dose Expansion - CapsulePhase 2 Dose Expansion - Tablet
Number (Proportion) of Participants With Adverse Events (AEs)75445309
PrimaryNumber (Proportion) of Participants With Dose-Limiting Toxicities (DLTs) in Phase 1b

Number (percentage) of patients experiencing a DLT during the first cycle (28 days) of study treatment in Phase 1b, defined as an adverse event (AE) or clinically significant abnormal laboratory value that was at least possibly related to study drugs and was not primarily related to disease, disease progression, concomitant medication(s), or intercurrent illness. In addition, to be considered a DLT, the AE had to meet at least one of the following criteria: * Grade 4 anemia unexplained by underlying disease * Grade 4 febrile neutropenia * Grade 4 neutropenia lasting \>5 days * Any other Grade 4 hematologic toxicity (thrombocytopenia, neutropenia, febrile neutropenia, anemia) of any duration * Grade 4 or higher tumor lysis syndrome * Grade 3 or higher thrombocytopenia (with or without bleeding) * Any requirement for platelet transfusion * Grade 3 or higher non-hematologic toxicity despite adequate supportive care * Results in a dose hold of \>7 consecutive days

Time frame:
Cycle 1 (28 days)
Reported as:
Count of participants · Participants
Number (Proportion) of Participants With Dose-Limiting Toxicities (DLTs) in Phase 1b
ParticipantsPhase 1b Dose Escalation Cohort 1Phase 1b Dose Escalation Cohort 2aPhase 1b Dose Escalation Cohort 2bPhase 1b Dose Escalation Cohort 2cPhase 1b Dose Escalation Cohort 3 (RP2D)
Number (Proportion) of Participants With Dose-Limiting Toxicities (DLTs) in Phase 1b40000
PrimaryOverall Response Rate

Number (percentage) of patients with a best overall complete response (CR) or partial response (PR) according to the Lugano 2014 criteria (Cheson, Bruce D. et al. J Clin Oncology 2014;32(27):3059-68), where CR included complete metabolic response (no/minimal fluorodeoxyglucose \[FDG\] uptake) and radiologic response (target lesions regress to ≤1.5 cm in longest transverse diameter of a lesion) and no new lesions, and PR included partial metabolic response (reduced FDG uptake compared with baseline) or radiologic response (target lesions ≤ 50% decrease in the sum of the product of perpendicular diameters of up to 6 target measurable nodes and extranodal sites)

Time frame:
Up to approximately 2 years
Reported as:
Count of participants · Participants
Overall Response Rate
ParticipantsPhase 1b Dose Escalation Cohort 1Phase 1b Dose Escalation Cohort 2aPhase 1b Dose Escalation Cohort 2bPhase 1b Dose Escalation Cohort 2cPhase 1b Dose Escalation Cohort 3Phase 2 Dose Expansion - CapsulePhase 2 Dose Expansion - Tablet
Complete Response2100131
Partial Response1110241
Stable Disease1001151
Progressive Disease20131115
SecondaryDuration of Response

Interval of time from date of first observed complete or partial response per Lugano 2014 criteria (Cheson BD et al. J Clin Oncology 2014;32(27):3059-68) to the date of documented disease progression or death due to any cause, where disease progression is defined by Lugano 2014 criteria (Cheson BD et al. J Clin Oncology 2014;32(27):3059-68) as progressive metabolic disease (increase in fluorodeoxyglucose \[FDG\] uptake from baseline or new FDG-avid foci consistent with lymphoma) or progressive radiologic response (increase in the product of perpendicular diameters of a single node by ≥ 50% or emergence of a new lesion)

Time frame:
Up to approximately 2 years
Reported as:
Median · days
Duration of Response
daysPhase 1b Dose Escalation Cohort 1Phase 1b Dose Escalation Cohort 2aPhase 1b Dose Escalation Cohort 2bPhase 1b Dose Escalation Cohort 2cPhase 1b Dose Escalation Cohort 3Phase 2 Dose Expansion - CapsulePhase 2 Dose Expansion - Tablet
Duration of Response825.5 (160.0 to NA)116.5 (34.0 to NA)113.0 (NA to NA)—NA (127.0 to NA)634.0 (80.0 to NA)NA (57.0 to NA)
SecondaryTime to Response

Interval of time from the start of study drug treatment to the first documentation of CR or PR per Lugano 2014 criteria (Cheson BD et al. J Clin Oncology 2014;32(27):3059-68)

Time frame:
Up to approximately 2 years
Reported as:
Median · days
Time to Response
daysPhase 1b Dose Escalation Cohort 1Phase 1b Dose Escalation Cohort 2aPhase 1b Dose Escalation Cohort 2bPhase 1b Dose Escalation Cohort 2cPhase 1b Dose Escalation Cohort 3Phase 2 Expansion - CapsulePhase 2 Expansion - Tablet
Time to ResponseNA (33.0 to NA)52.5 (51.0 to NA)NA (50.0 to NA)—NA (57.0 to NA)162.0 (58.0 to NA)NA (58.0 to NA)
SecondaryProgression-Free Survival

Interval of time from the date of first study drug administration to the documented date of disease progression or death, whichever occurred first, where disease progression is defined by Lugano 2014 criteria (Cheson BD et al. J Clin Oncology 2014;32(27):3059-68) as progressive metabolic disease (increase in fluorodeoxyglucose \[FDG\] uptake from baseline or new FDG-avid foci consistent with lymphoma) or progressive radiologic response (increase in the product of perpendicular diameters of a single node by ≥ 50% or emergence of a new lesion)

Time frame:
Up to approximately 2 years
Reported as:
Median · days
Progression-Free Survival
daysPhase 1b Dose Escalation Cohort 1Phase 1b Dose Escalation Cohort 2aPhase 1b Dose Escalation Cohort 2bPhase 1b Dose Escalation Cohort 2cPhase 1b Dose Escalation Cohort 3Phase 2 Expansion - CapsulePhase 2 Expansion - Tablet
Progression-Free Survival209.0 (57.0 to NA)168.0 (87.0 to NA)107.5 (53.0 to NA)55.5 (15.0 to NA)185.0 (10.0 to NA)66.0 (56.0 to 220.0)52.5 (34.0 to 114.0)
SecondaryDisease Control Rate

Number (percentage) of patients with CR, PR, or stable disease (SD) per Lugano 2014 criteria (Cheson BD et al. J Clin Oncology 2014;32(27):3059-68)

Time frame:
Up to approximately 2 years
Reported as:
Count of participants · Participants
Disease Control Rate
ParticipantsPhase 1b Dose Escalation Cohort 1Phase 1b Dose Escalation Cohort 2aPhase 1b Dose Escalation Cohort 2bPhase 1b Dose Escalation Cohort 2cPhase 1b Dose Escalation Cohort 3Phase 2 Expansion - CapsulePhase 2 Expansion - Tablet
Disease Control Rate42114123
SecondaryOverall Survival

Interval of time from date of first study drug treatment to date of death, for any reason (patients without documentation of death at the time of analysis were censored at the date the patient was last known to be alive)

Time frame:
Up to approximately 2 years
Reported as:
Median · days
Overall Survival
daysPhase 1b Dose Escalation Cohort 1Phase 1b Dose Escalation Cohort 2aPhase 1b Dose Escalation Cohort 2bPhase 1b Dose Escalation Cohort 2cPhase 1b Dose Escalation Cohort 3Phase 2 Expansion - CapsulePhase 2 Expansion - Tablet
Overall Survival227.0 (122.0 to NA)578.0 (486.0 to NA)NA (328.0 to NA)168.5 (32.0 to NA)496.0 (49.0 to NA)801.0 (315.0 to NA)NA (106.0 to NA)
SecondaryCmax (ng/mL) of VRx-3996

Pharmacokinetic (PK) assessment of VRx-3996 pre-dose and at hours 0.5, 1, 2, 4, and 6 post-dose on cycle 1 day 1 (C1D1) and cycle 2 day 2 (C2D1)

Time frame:
Phase 1b: Cycle 1 Day 1 and Phase 2: multiple doses through Cycle 2 Day 1
Reported as:
Mean · ng/mL
Cmax (ng/mL) of VRx-3996
ng/mLPhase 1b Dose Escalation Cohort 2aPhase 1b Dose Escalation Cohorts 1, 2b and 2cPhase 1b Dose Escalation Cohort 3Phase 2 RP2D - CapsulePhase 2 RP2D - Tablet
Single-dose29.8 ± 26.783.3 ± 38.1214 ± 140196 ± 166298 ± 137
Multiple-dose———334 ± 283238 ± 208
SecondaryCmax (ng/mL) of Valganciclovir

PK assessment of valganciclovir pre-dose and at hours 0.5, 1, 2, 4, and 6 post-dose on C1D1 and C2D1

Time frame:
Phase 1b: Cycle 1 Day 1 and Phase 2: multiple doses through Cycle 2 Day 1
Reported as:
Mean · ng/mL
Cmax (ng/mL) of Valganciclovir
ng/mLPhase 1b Dose Escalation - 450 mgPhase 1b Dose Escalation - 900 mgPhase 2 RP2D - Capsule (VRx-3996)Phase 2 RP2D - Tablet (VRx-3996)
Single-Dose4230 ± 13486712 ± 14957300 ± 279014900 ± 8380
Multiple-Dose——8690 ± 580014200 ± 7060
SecondaryArea Under Curve (AUC) 0-t of VRx-3996

PK assessment of VRx-3996 pre-dose and at hours 0.5, 1, 2, 4, and 6 post-dose on C1D1 and C2D1

Time frame:
Phase 1b: Cycle 1 Day 1 and Phase 2: multiple doses through Cycle 2 Day 1
Reported as:
Mean · h*ng/mL
Area Under Curve (AUC) 0-t of VRx-3996
h*ng/mLPhase 1b Dose Escalation Cohort 2aPhase 1b Dose Escalation Cohorts 1, 2b and 2cPhase 1b Dose Escalation Cohort 3Phase 2 RP2D - CapsulePhase 2 RP2D - Tablet
Single-dose128 ± 67.0229 ± 76.4340 ± 384417 ± 299587 ± 212
Multiple-dose———638 ± 418474 ± 268
SecondaryAUC 0-t of of Valganciclovir

PK assessment of valganciclovir pre-dose and at hours 0.5, 1, 2, 4, and 6 post-dose on C1D1 and C2D1

Time frame:
Phase 1b: Cycle 1 Day 1 and Phase 2: multiple doses through Cycle 2 Day 1
Reported as:
Mean · h*ng/mL
AUC 0-t of of Valganciclovir
h*ng/mLPhase 1b Dose Escalation - 450 mgPhase 1b Dose Escalation - 900 mgPhase 2 RP2D - Capsule (VRx-3996)Phase 2 RP2D - Tablet (VRx-3996)
Single-dose15600 ± 416024400 ± 930025200 ± 1040049700 ± 29100
Multiple-dose——28300 ± 1640046600 ± 18000
SecondaryHalf-life of VRx-3996

PK assessment of VRx-3996 pre-dose and at hours 0.5, 1, 2, 4, and 6 post-dose on C1D1 and C2D1

Time frame:
Phase 1b: Cycle 1 Day 1 and Phase 2: multiple doses through Cycle 2 Day 1
Reported as:
Mean · hours
Half-life of VRx-3996
hoursPhase 1b Dose Escalation Cohort 2aPhase 1b Dose Escalation Cohorts 1, 2b and 2cPhase 1b Dose Escalation Cohort 3Phase 2 RP2D - CapsulePhase 2 RP2D - Tablet
Single-dose1.89 ± 0.2521.44 ± 0.466—1.46 ± 0.5891.43 ± 0.287
Multiple-dose———1.10 ± 0.1811.87 ± 1.33
SecondaryHalf-life of Valganciclovir

PK assessment of valganciclovir pre-dose and at hours 0.5, 1, 2, 4, and 6 post-dose on C1D1 and C2D1

Time frame:
Phase 1b: Cycle 1 Day 1 and Phase 2: multiple doses through Cycle 2 Day 1
Reported as:
Mean · hours
Half-life of Valganciclovir
hoursPhase 1b Dose Escalation - 450 mgPhase 1b Dose Escalation - 900 mgPhase 2 RP2D - Capsule (VRx-3996)Phase 2 RP2D - Tablet (VRx-3996)
Single-dose3.56 ± 1.063.13 ± 1.433.32 ± 1.102.17 ± 1.68
Multiple-dose——2.43 ± 0.6972.61 ± 1.55

Adverse events

Collected over Up to approximately 2 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1b Dose Escalation Cohort 14/7 (57.1%)2/7 (28.6%)7/7 (100%)
Phase 1b Dose Escalation Cohort 2a4/5 (80%)2/5 (40%)5/5 (100%)
Phase 1b Dose Escalation Cohort 2b2/4 (50%)2/4 (50%)4/4 (100%)
Phase 1b Dose Escalation Cohort 2c4/4 (100%)1/4 (25%)4/4 (100%)
Phase 1b Dose Escalation Cohort 33/5 (60%)1/5 (20%)5/5 (100%)
Phase 2 Dose Expansion - Capsule17/30 (56.7%)11/30 (36.7%)22/30 (73.3%)
Phase 2 Dose Expansion - Tablet4/9 (44.4%)4/9 (44.4%)6/9 (66.7%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventPhase 1b Dose Escalation Cohort 1Phase 1b Dose Escalation Cohort 2aPhase 1b Dose Escalation Cohort 2bPhase 1b Dose Escalation Cohort 2cPhase 1b Dose Escalation Cohort 3Phase 2 Dose Expansion - CapsulePhase 2 Dose Expansion - Tablet
Tumour necrosisNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/70/50/41/40/50/300/9
Acute kidney injuryRenal and urinary disorders0/70/51/40/40/51/300/9
Enterocolitis viralInfections and infestations0/70/51/40/40/50/300/9
PharyngitisInfections and infestations0/70/50/41/40/50/300/9
DyspnoeaRespiratory, thoracic and mediastinal disorders0/71/50/40/40/50/301/9
PyrexiaGeneral disorders0/71/50/40/40/50/301/9
Clostridium difficile colitisInfections and infestations0/71/50/40/40/50/300/9
Left ventricular failureCardiac disorders0/71/50/40/40/50/300/9
Drug hypersensitivityImmune system disorders0/71/50/40/40/50/300/9
Systemic lupus erythematosusMusculoskeletal and connective tissue disorders0/70/50/40/41/50/300/9
Most frequent other events
Showing 10 of 52
Most frequent other events
EventPhase 1b Dose Escalation Cohort 1Phase 1b Dose Escalation Cohort 2aPhase 1b Dose Escalation Cohort 2bPhase 1b Dose Escalation Cohort 2cPhase 1b Dose Escalation Cohort 3Phase 2 Dose Expansion - CapsulePhase 2 Dose Expansion - Tablet
ConstipationGastrointestinal disorders1/74/50/42/42/58/302/9
NauseaGastrointestinal disorders1/70/53/41/44/511/305/9
VomitingGastrointestinal disorders1/70/53/40/42/56/303/9
HeadacheNervous system disorders1/70/53/40/40/53/300/9
FatigueGeneral disorders4/71/50/40/41/510/306/9
Blood creatinine increasedInvestigations3/71/50/40/43/53/301/9
Oedema peripheralGeneral disorders4/70/50/40/40/51/301/9
ThrombocytopeniaGastrointestinal disorders2/72/50/42/40/55/300/9
DiarrhoeaGastrointestinal disorders3/72/52/40/41/57/304/9
PyrexiaGeneral disorders0/72/52/40/41/56/302/9

Baseline characteristics

Starting valganciclovir dosage reductions based on creatinine clearance were allowed for participants with renal impairment.

Age, Categorical
Age, Categorical(Participants)Phase 1b Dose Escalation Cohort 1Phase 1b Dose Escalation Cohort 2aPhase 1b Dose Escalation Cohort 2bPhase 1b Dose Escalation Cohort 2cPhase 1b Dose Escalation Cohort 3Phase 2 Dose Expansion - CapsulePhase 2 Dose Expansion - TabletTotal
<=18 years00000000
Between 18 and 65 years4243414334
>=65 years3301116630
Age, Continuous
Age, Continuous(years)Phase 1b Dose Escalation Cohort 1Phase 1b Dose Escalation Cohort 2aPhase 1b Dose Escalation Cohort 2bPhase 1b Dose Escalation Cohort 2cPhase 1b Dose Escalation Cohort 3Phase 2 Dose Expansion - CapsulePhase 2 Dose Expansion - TabletTotal
Mean55.0 ± 24.0660.8 ± 20.4445.3 ± 19.4556.8 ± 10.5644.0 ± 24.3660.1 ± 16.9763.4 ± 15.4257.7 ± 18.42
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1b Dose Escalation Cohort 1Phase 1b Dose Escalation Cohort 2aPhase 1b Dose Escalation Cohort 2bPhase 1b Dose Escalation Cohort 2cPhase 1b Dose Escalation Cohort 3Phase 2 Dose Expansion - CapsulePhase 2 Dose Expansion - TabletTotal
Female1221212424
Male6323318540
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1b Dose Escalation Cohort 1Phase 1b Dose Escalation Cohort 2aPhase 1b Dose Escalation Cohort 2bPhase 1b Dose Escalation Cohort 2cPhase 1b Dose Escalation Cohort 3Phase 2 Dose Expansion - CapsulePhase 2 Dose Expansion - TabletTotal
Hispanic or Latino000128112
Not Hispanic or Latino7543322751
Unknown or Not Reported00000011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 1b Dose Escalation Cohort 1Phase 1b Dose Escalation Cohort 2aPhase 1b Dose Escalation Cohort 2bPhase 1b Dose Escalation Cohort 2cPhase 1b Dose Escalation Cohort 3Phase 2 Dose Expansion - CapsulePhase 2 Dose Expansion - TabletTotal
American Indian or Alaska Native00000000
Asian10100215
Native Hawaiian or Other Pacific Islander00000000
Black or African American01101205
White6423324850
More than one race00000202
Unknown or Not Reported00011002
Region of Enrollment
Region of Enrollment(Participants)Phase 1b Dose Escalation Cohort 1Phase 1b Dose Escalation Cohort 2aPhase 1b Dose Escalation Cohort 2bPhase 1b Dose Escalation Cohort 2cPhase 1b Dose Escalation Cohort 3Phase 2 Dose Expansion - CapsulePhase 2 Dose Expansion - TabletTotal
United States7543320951
Brazil0001210013
Lymphoma or Lymphoproliferative Disorder Subtype
Lymphoma or Lymphoproliferative Disorder Subtype(Participants)Phase 1b Dose Escalation Cohort 1Phase 1b Dose Escalation Cohort 2aPhase 1b Dose Escalation Cohort 2bPhase 1b Dose Escalation Cohort 2cPhase 1b Dose Escalation Cohort 3Phase 2 Dose Expansion - CapsulePhase 2 Dose Expansion - TabletTotal
Peripheral T-cell Lymphoma / Angioimmunoblastic T-cell Lymphoma121007213
Diffuse Large B-cell Lymphoma110005310
Extranodal NK/T-cell Lymphoma001026110
Human Immunodeficiency Virus-Associated Lymphoma10120105
Hodgkin Lymphoma200117112
Immunodeficiency-Associated Lymphoproliferative Disorders01101104
Other B-cell Non-Hodgkin Lymphomas10000214
Other T-cell Non-Hodgkin Lymphomas00010012
Post-Transplant Lymphoproliferative Disorders11001104
08

Study locations

28 sites
  • USC Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • University of California, Los Angeles
    Los Angeles, California 90404, United States
  • UC Irvine Chao Family Comprehensive Cancer Center
    Orange, California 92868, United States
  • University of Colorado Anschutz Cancer Pavilion
    Aurora, Colorado 80045, United States
  • Mid Florida Hematology and Oncology Center
    Orange City, Florida 32763, United States
  • ASCLEPES Research Centers
    Weeki Wachee, Florida 34607, United States
  • Winship Cancer Institute, Emory University
    Atlanta, Georgia 30322, United States
  • Georgia Cancer Center at Augusta University
    Augusta, Georgia 30912, United States
  • Northwestern University Feinberg School of Medicine
    Chicago, Illinois 60611, United States
  • Ruth M Rothstein CORE Center
    Chicago, Illinois 60612, United States
  • Indiana Blood and Marrow Transplantation
    Indianapolis, Indiana 46237, United States
  • The University of Kansas Cancer Center and Medical Pavilion
    Westwood, Kansas 66205, United States
  • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Baltimore, Maryland 21231, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • St. Vincent Healthcare Cancer Center
    Billings, Montana 59102, United States
  • John Theurer Cancer Center at Hackensack UMC
    Hackensack, New Jersey 07601, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Weill Cornell Medical College - New York Presbyterian Hospital
    New York, New York 10065, United States
  • The Ohio State University Wexner Medical Center James Cancer Hospital
    Columbus, Ohio 43210, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • Texas Oncology - Baylor Sammons Cancer Center
    Dallas, Texas 75246, United States
  • Centro de Hematologia e Oncologia da Bahia (CEHON)
    Salvador, BA 40110-090, Brazil
  • Hospital de Cancer de Pernambuco (HCP)
    Recife, PE 50040-000, Brazil
  • Hospital do Cancer Mae de Deus
    Porto Alegre, Rio Grande Do Sul, Brazil
  • Real e Benemerita Associacao Portuguesa de Beneficencia
    São Paulo, SP 01321-001, Brazil
  • Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC-FMUSP)
    São Paulo, SP 05403-000, Brazil
  • Hospital Santa Marcelina
    São Paulo, SP 08270-070, Brazil
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2018 to primary completion in Apr 2023, 60 months.

Results were first posted in Mar 2025, 1 year 11 months after primary completion. A results delay was requested in Mar 2024.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2017
First posted
Jan 12, 2018
StartActual
Mar 29, 2018
Primary completionActual
Apr 1, 2023
CompletionActual
May 4, 2023
Results delay requested
Mar 1, 2024
Results first posted
Mar 20, 2025
Last update
Mar 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03397706
Lead sponsor
Viracta Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jan 12, 2018
Start date
Mar 29, 2018
Primary completion
Apr 1, 2023
Completion
May 4, 2023
Results posted
Mar 20, 2025
Last update
Mar 20, 2025

Study contacts

Jill DeFratis Robinson
study director · Viracta Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nanatinostat · Valganciclovir

Start the discussion